Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $800 thousand versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.